Comparative Pharmacology
Head-to-head clinical analysis: HIPREX versus MACROBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPREX versus MACROBID.
HIPREX vs MACROBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hippuric acid, the active metabolite of methenamine, acidifies urine and releases formaldehyde, which denatures bacterial proteins and nucleic acids, bactericidal activity requires acidic urine (pH < 5.5).
Nitrofurantoin is a urinary tract antibacterial agent that inhibits bacterial acetyl-CoA carboxylase, disrupting cell wall synthesis and bacterial respiration. It is reduced by bacterial nitroreductases to reactive intermediates that damage DNA, ribosomes, and other macromolecules.
1 gram orally twice daily (every 12 hours) with meals
100 mg orally twice daily with food for 7 days.
None Documented
None Documented
3-6 hours (methenamine); clinical context: prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 0.3-1.0 hour (short) due to rapid renal clearance and tissue metabolism; no accumulation with twice-daily dosing. The short half-life is adequate for urinary tract exposure.
Renal excretion: >90% as unchanged drug (methenamine) and formaldehyde; biliary/fecal: <5%.
Renal: 36% (unchanged nitrofurantoin) and 15% (metabolites) within 24 hours. Total renal elimination: 51%. Biliary/fecal: 1-2%. Additional 30% undergoes rapid metabolic degradation in tissues.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective